Woodline Partners LP Next Cure, Inc. Transaction History

Woodline Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.27 $546,336 - $851,832	-161,638 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $2.83 Million - $3.71 Million	-594,358 Reduced 78.62%	161,638 $786,000
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $4.31 Million - $6.88 Million	755,996 New	755,996 $4.54 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $37.2M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.